This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dyax Corp. To Participate In November 2012 Healthcare Conferences

Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in two upcoming conferences.

Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Wednesday, November 14 at 11:20 AM (GMT), at the Jefferies 2012 Global Healthcare Conference, being held November 14-15, 2012 in London, England.

Mr. Christensen will also present at Piper Jaffray’s 24 th Annual Healthcare Conference, on Tuesday November 27 at 4:30 PM (ET). The conference is being held November 27-28, at The New York Palace Hotel in New York City.

At both events, Mr. Christensen will provide a corporate update regarding the Company’s key value drivers – KALBITOR ® (ecallantide) and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).

Both presentations will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.dyax.com. The webcasts will also be available on the Dyax website for a limited period of time following the conferences.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key value drivers are the KALBITOR ® (ecallantide) business and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).

Dyax developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others.

The Company is currently developing products to expand its angioedema portfolio, including a diagnostic strategy to identify plasma kallikrein (bradykinin) mediated (PKM) angioedema and a therapeutic candidate, DX-2930, for the prophylactic treatment of PKM angioedema.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs